首页 > 市场调查报告书 > 製药

眼科药物

市场调查报告书

商品编码

1524270

无虹膜治疗市场- 依治疗类型（药物[眼药水、药膏]、手术[人工虹膜植入术、前房角切开术]）、类型（先天性[孤立性、WAGR 症候群、吉莱斯皮肤综合症]、后天）、年龄层- 全球预测（2024 年 -第2032章

Aniridia Treatment Market - By Treatment Type (Medication [Eye Drop, Ointment], Surgery [Artificial Iris Implantation, Goniotomy]), Type (Congenital [Isolated, WAGR Syndrome, Gillespie Syndrome], Acquired), Age Group - Global Forecast (2024 - 2032)

出版日期: 2024年04月29日 | 出版商:

Global Market Insights Inc. | 英文 150 Pages | 商品交期: 2-3个工作天内

价格

简介目录

由于医疗保健支出不断增加以及 RampD 的大量投资，预计 2024 年至 2032 年全球无虹膜治疗市场规模的复合年增长率将达到 5.1%。不断增长的财政支持正在推动创新疗法和个人化治疗方法的探索，以改善患者的治疗效果。

随着医疗保健支出的激增，人们不断努力增强无虹膜症的诊断工具和治疗选择。此外，医学研究人员、临床医生和药物开发人员之间的合作将进一步加速新疗法的发现，例如基因编辑技术和干细胞疗法。根据美国医学会的数据，2022年美国医疗保健支出成长4.1%，达到4.5兆美元，即人均13,493美元。这一增长可能会增加无虹膜治疗和研究项目进展的资金支持。

市场分为治疗类型、类型、年龄层和地区。

以治疗类型来看，从 2024 年到 2032 年，药物领域的无虹膜治疗行业预计将以显着的速度增长。和角膜併发症。正在进行的研究正在帮助探索新的治疗类型，包括基因疗法和基于干细胞的方法，以解决导致无虹膜的潜在基因突变。创新疗法还可以改善视力结果并有可能阻止疾病进展。

后天无虹膜类型细分市场的无虹膜治疗市场预计将从2024 年扩大到2032 年。併发症。人们迫切需要使用矫正镜片和药物来缓解眩光和视力下降等症状。最近，对后天性无虹膜症的研究有助于制定适合个别患者需求的个人化治疗计划，同时优化治疗效果以提高视觉舒适度和生活品质。

从地区来看，在基因检测和旨在增强诊断和个性化治疗方法的咨询倡议的兴起的推动下，欧洲无虹膜治疗行业规模预计将在 2024 年至 2032 年间实现利润丰厚的增长。这些努力正在为基因定序和生物标记研究等技术创新让路，以便更好地了解无虹膜的遗传基础。解决无虹膜根本原因并为欧洲患者提供更有效的治疗选择的持续发展也将促进市场成长。

主要趋势
药物
- 类型
  - 眼药水
  - 药膏
  - 其他药物类型
- 配销通路
  - 医院药房
  - 零售药局
  - 网路药局
手术
- 手术类型
  - 角膜移植术
  - 人工虹膜植入术
  - 青光眼引流装置
  - 小梁切除术
  - 房角切开术
  - 其他手术类型
- 最终用户
  - 医院
  - 专科诊所
  - 门诊手术中心
  - 其他最终用户

第 6 章：市场估计与预测：按类型，2021 - 2032

主要趋势
先天性无虹膜
- 孤立性无虹膜
- WAGR症候群
- 吉莱斯皮症候群
后天无虹膜症

第 7 章：市场估计与预测：按年龄划分，2021 - 2032

主要趋势
儿科
成人

第 8 章：市场估计与预测：按地区，2021 - 2032

主要趋势
北美洲
- 我们
- 加拿大
欧洲
- 德国
- 英国
- 法国
- 西班牙
- 义大利
- 荷兰
- 欧洲其他地区
亚太地区
- 日本
- 中国
- 印度
- 澳洲
- 韩国
- 亚太地区其他地区
拉丁美洲
- 巴西
- 墨西哥
- 拉丁美洲其他地区
中东和非洲
- 沙乌地阿拉伯
- 南非
- 阿联酋
- 中东和非洲其他地区

第 9 章：公司简介

AbbVie Inc.
Bausch & Lomb Incorporated
F. Hoffmann-La Roche Ltd
HumanOptics AG
Johnson & Johnson Vision
MORCHER GmbH
Novartis AG
Ophtec
Pfizer Inc.
REPER-NN LTD.

简介目录

Product Code: 9264

Global Aniridia Treatment Market size is anticipated to record 5.1% CAGR from 2024 to 2032, due to rising healthcare expenditure along with significant R&D investments. Growing financial support is enabling the exploration of innovative therapies and personalized treatment approaches to improve patient outcomes.

With the surging healthcare spending, there are ongoing efforts for enhancing diagnostic tools and therapeutic options for aniridia. Moreover, the collaborations between medical researchers, clinicians, and pharmaceutical developers will further accelerate the discovery of novel treatments, such as gene editing technologies and stem cell therapies. According to American Medical Association, the health spending in the U.S. increased by 4.1% in 2022 to 4.5 trillion or 13,493 per capita. This rise may potentially bolster the funding for advancements in aniridia treatment and research initiatives.

The market is segmented into treatment type, type, age group, and region.

By treatment type, the aniridia treatment industry from the medication segment is estimated to rise at a significant rate from 2024 to 2032. This is due to increasing medication options, such as topical therapies and the use of off-label for managing symptoms, such as photophobia and corneal complications. Ongoing research is helping in exploring new treatment types including gene therapy and stem cell-based approaches for addressing the underlying genetic mutations that cause aniridia. Innovative therapies are also improving vision outcomes and potentially halting disease progression.

Aniridia treatment market from the acquired aniridia type segment is expected to expand from 2024 to 2032. This is propelled by the approaches in acquired aniridia treatment for managing symptoms and complications resulting from trauma, surgery, or other acquired causes. There is a surging need for therapies to alleviate symptoms, such as glare and decreased visual acuity using corrective lenses and medications. Lately, research into acquired aniridia is helping in developing personalized treatment plans tailored to individual patient needs while optimizing therapeutic efficacy to enhance visual comfort and quality of life.

Regionally, the Europe aniridia treatment industry size is projected to depict lucrative growth between 2024 and 2032, propelled by the rise in genetic testing and counseling initiatives for enhancing diagnosis and personalized treatment approaches. These efforts are making way for technological innovations like genetic sequencing and biomarker research to better understand the genetic basis of aniridia. Increasing developments, for addressing the root causes of aniridia and offering more effective treatment options for patients across Europe will also boost the market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates & calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Rising incidence rate of aniridia
  - 3.2.1.2 Increasing awareness for rare diseases
  - 3.2.1.3 Growing R&D investment
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

5.1 Key trends
5.2 Medication
- 5.2.1 Type
  - 5.2.1.1 Eye drop
  - 5.2.1.2 Ointments
  - 5.2.1.3 Other medication types
- 5.2.2 Distribution channel
  - 5.2.2.1 Hospital pharmacies
  - 5.2.2.2 Retail pharmacies
  - 5.2.2.3 Online pharmacies
5.3 Surgery
- 5.3.1 Surgery type
  - 5.3.1.1 Keratoplasty
  - 5.3.1.2 Artificial iris implantation
  - 5.3.1.3 Glaucoma drainage devices
  - 5.3.1.4 Trabeculectomy
  - 5.3.1.5 Goniotomy
  - 5.3.1.6 Other surgery types
- 5.3.2 End-user
  - 5.3.2.1 Hospitals
  - 5.3.2.2 Specialty clinics
  - 5.3.2.3 Ambulatory surgical centers
  - 5.3.2.4 Other end-users

Chapter 6 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

6.1 Key trends
6.2 Congenital aniridia
- 6.2.1 Isolated aniridia
- 6.2.2 WAGR syndrome
- 6.2.3 Gillespie syndrome
6.3 Acquired aniridia

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 - 2032 ($ Mn)

7.1 Key trends
7.2 Pediatric
7.3 Adult

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

8.1 Key trends
8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
8.3 Europe
- 8.3.1 Germany
- 8.3.2 UK
- 8.3.3 France
- 8.3.4 Spain
- 8.3.5 Italy
- 8.3.6 Netherlands
- 8.3.7 Rest of Europe
8.4 Asia Pacific
- 8.4.1 Japan
- 8.4.2 China
- 8.4.3 India
- 8.4.4 Australia
- 8.4.5 South Korea
- 8.4.6 Rest of Asia Pacific
8.5 Latin America
- 8.5.1 Brazil
- 8.5.2 Mexico
- 8.5.3 Rest of Latin America
8.6 Middle East and Africa
- 8.6.1 Saudi Arabia
- 8.6.2 South Africa
- 8.6.3 UAE
- 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

9.1 AbbVie Inc.
9.2 Bausch & Lomb Incorporated
9.3 F. Hoffmann-La Roche Ltd
9.4 HumanOptics AG
9.5 Johnson & Johnson Vision
9.6 MORCHER GmbH
9.7 Novartis AG
9.8 Ophtec
9.9 Pfizer Inc.
9.10 REPER-NN LTD.

02-2729-4219

+886-2-2729-4219

License/价格